Variable | Category | |
---|---|---|
Age, years | Median | 63 |
IQR | 54–70 | |
Gender, n (%) | Female | 145 (26.1) |
Male | 411 (73.9) | |
T stage, n (%) | pT1 | 370 (66.5) |
pT2 | 61 (11.0) | |
pT3 | 123 (22.1) | |
pT4 | 2 (0.4) | |
N stage, n (%) | pNx/pN0 | 537 (96.6) |
pN1 | 19 (3.4) | |
Nuclear grade, n (%) | 1 or 2 | 381 (68.5) |
3 or 4 | 175 (31.5) | |
Tumour size, n (%) | 4.0 cm or less | 285 (51.3) |
4.1 to 10.0 cm | 219 (39.4) | |
10.1 cm or greater | 52 (9.4) | |
Median | 4.0 | |
IQR | 2.7–6.3 | |
Surgical margin, n (%) | Negative | 525 (94.4) |
Positive | 31 (5.6) | |
Venous tumour thrombus, n (%) | None | 524 (94.2) |
Renal vein | 15 (2.7) | |
Cava | 17 (3.1) | |
Perinephric/sinus fat invasion, no venous tumour thrombus, n (%) | – | 93 (16.7) |
Papillary type, n (%) | Type 1 | 227 (46.0) |
Type 2 | 266 (54.0) | |
Tumour necrosis, n (%) | – | 254 (45.7) |
Sarcomatoid features, n (%) | – | 11 (2.0) |
UISS, n (%) | Low/intermediate risk | 335 (60.3) |
Intermediate high risk | 141 (25.4) | |
Very high risk | 80 (14.4) | |
2018 Leibovich group, n (%) | Low (group 1) | 322 (57.9) |
Intermediate (group 2) | 102 (18.3) | |
High (group 3) | 132 (23.7) | |
TNM group, n (%) | I | 369 (66.4) |
II | 60 (10.8) | |
III | 125 (22.5) | |
IV | 2 (0.4) |